TECH Quote, Financials, Valuation and Earnings

Avantor has a net margin of 7.14% compared to Bio-Techne's net margin of 4.08%. Bio-Techne's return on equity of 6.38% beat Avantor's return on equity of 12.61%.

Bio-Techne has a consensus price target of $68.95, signalling upside risk potential of 38.2%. On the other hand Avantor has an analysts' consensus of $17.15 which suggests that it could grow by 26.38%. Given that Bio-Techne has higher upside potential than Avantor, analysts believe Bio-Techne is more attractive than Avantor.

Bio-Techne has a beta of 1.382, which suggesting that the stock is 38.244% more volatile than S&P 500. In comparison Avantor has a beta of 1.041, suggesting its more volatile than the S&P 500 by 4.069%.

Bio-Techne has a quarterly dividend of $0.08 per share corresponding to a yield of 0.64%. Avantor offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Techne pays 29.99% of its earnings as a dividend. Avantor pays out -- of its earnings as a dividend. Bio-Techne's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bio-Techne quarterly revenues are $316.2M, which are smaller than Avantor quarterly revenues of $1.6B. Bio-Techne's net income of $22.6M is lower than Avantor's net income of $64.5M. Notably, Bio-Techne's price-to-earnings ratio is 60.84x while Avantor's PE ratio is 13.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Techne is 6.62x versus 1.39x for Avantor. Usually stocks with elevated PS ratios are considered overvalued.

Bio-Rad Laboratories has a net margin of 7.14% compared to Bio-Techne's net margin of 10.93%. Bio-Techne's return on equity of 6.38% beat Bio-Rad Laboratories's return on equity of -29.59%.

Bio-Techne has a consensus price target of $68.95, signalling upside risk potential of 38.2%. On the other hand Bio-Rad Laboratories has an analysts' consensus of $314.33 which suggests that it could grow by 32.78%. Given that Bio-Techne has higher upside potential than Bio-Rad Laboratories, analysts believe Bio-Techne is more attractive than Bio-Rad Laboratories.

Bio-Techne has a beta of 1.382, which suggesting that the stock is 38.244% more volatile than S&P 500. In comparison Bio-Rad Laboratories has a beta of 0.932, suggesting its less volatile than the S&P 500 by 6.799%.

Bio-Techne has a quarterly dividend of $0.08 per share corresponding to a yield of 0.64%. Bio-Rad Laboratories offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Techne pays 29.99% of its earnings as a dividend. Bio-Rad Laboratories pays out -- of its earnings as a dividend. Bio-Techne's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bio-Techne quarterly revenues are $316.2M, which are smaller than Bio-Rad Laboratories quarterly revenues of $585.4M. Bio-Techne's net income of $22.6M is lower than Bio-Rad Laboratories's net income of $64M. Notably, Bio-Techne's price-to-earnings ratio is 60.84x while Bio-Rad Laboratories's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Techne is 6.62x versus 2.62x for Bio-Rad Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

Bruker has a net margin of 7.14% compared to Bio-Techne's net margin of 2.17%. Bio-Techne's return on equity of 6.38% beat Bruker's return on equity of 4.53%.

Bio-Techne has a consensus price target of $68.95, signalling upside risk potential of 38.2%. On the other hand Bruker has an analysts' consensus of $55.97 which suggests that it could grow by 46.99%. Given that Bruker has higher upside potential than Bio-Techne, analysts believe Bruker is more attractive than Bio-Techne.

Bio-Techne has a beta of 1.382, which suggesting that the stock is 38.244% more volatile than S&P 500. In comparison Bruker has a beta of 1.156, suggesting its more volatile than the S&P 500 by 15.599%.

Bio-Techne has a quarterly dividend of $0.08 per share corresponding to a yield of 0.64%. Bruker offers a yield of 0.53% to investors and pays a quarterly dividend of $0.05 per share. Bio-Techne pays 29.99% of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Bio-Techne quarterly revenues are $316.2M, which are smaller than Bruker quarterly revenues of $801.4M. Bio-Techne's net income of $22.6M is higher than Bruker's net income of $17.4M. Notably, Bio-Techne's price-to-earnings ratio is 60.84x while Bruker's PE ratio is 73.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Techne is 6.62x versus 1.67x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Novavax has a net margin of 7.14% compared to Bio-Techne's net margin of 82.81%. Bio-Techne's return on equity of 6.38% beat Novavax's return on equity of --.

Bio-Techne has a consensus price target of $68.95, signalling upside risk potential of 38.2%. On the other hand Novavax has an analysts' consensus of $13.43 which suggests that it could grow by 109.49%. Given that Novavax has higher upside potential than Bio-Techne, analysts believe Novavax is more attractive than Bio-Techne.

Bio-Techne has a beta of 1.382, which suggesting that the stock is 38.244% more volatile than S&P 500. In comparison Novavax has a beta of 2.803, suggesting its more volatile than the S&P 500 by 180.302%.

Bio-Techne has a quarterly dividend of $0.08 per share corresponding to a yield of 0.64%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Techne pays 29.99% of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend. Bio-Techne's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bio-Techne quarterly revenues are $316.2M, which are smaller than Novavax quarterly revenues of $626.3M. Bio-Techne's net income of $22.6M is lower than Novavax's net income of $518.6M. Notably, Bio-Techne's price-to-earnings ratio is 60.84x while Novavax's PE ratio is 2.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Techne is 6.62x versus 0.88x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.